Myths and Misconceptions around Antibiotic Resistance: Time to Get Rid of Them

키워드

참고문헌 (77)

1. Spellberg B, "On the exoneration of Dr. William H. Stewart : debunking an urban legend", Infect Dis Poverty, 2, pp.3~ (2013)
2. Amábile-Cuevas CF, "Antibiotic resistance from, and to the environment", AIMS Environ Sci, 8, pp.18~35 (2021)
3. Windels EM, "Antibiotics : combatting tolerance to stop resistance", MBio, 10, pp.e02095-19~ (2019)
4. Bakkeren E, "Salmonella persisters promote the spread of antibiotic resistance plasmids in the gut", Nature, 573, pp.276~280 (2019)
5. Rinder H, "Hetero-resistance : an under-recognised confounder in diagnosis and therapy?", J Med Microbiol, 50, pp.1018~1020 (2001)
6. Amábile-Cuevas CF, "Antibiotic resistance : from Darwin to Lederberg to Keynes", Microb Drug Resist, 19, pp.73~87 (2013)
7. Spellberg B, "The maturing antibiotic mantra : "Shorter is still better"", J Hosp Med, 13, pp.361~362 (2018)
8. Gilbert GL, "Knowing when to stop antibiotic therapy", Med J Aust, 202, pp.121~122 (2015)
9. Spellberg B, "The new antibiotic mantra-"shorter is better"", JAMA Intern Med, 176, pp.1254~1255 (2016)
10. Levy-Hara G, ""Ten commandments"for the appropriate use of antibiotics by the practicing physician in an outpatient setting", Front Microbiol, 2, pp.230~ (2011)
11. Craig WA, "Antimicrobial pharmacodynamics in theory and clinical practice", pp.1~22 (2002), Marcel Dekker
12. Amábile-Cuevas CF, "Antimicrobial resistance in developing countries", pp.3~13 (2010), Springer
13. Llewelyn MJ, "The antibiotic course has had its day", BMJ, 358, pp.j3418~ (2017)
14. Chung H, "Rapid expansion and extinction of antibiotic resistance mutations during treatment of acute bacterial respiratory infections", Nat Commun, 13, pp.1231~ (2022)
15. Oliver A, "Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance", Clin Microbiol Infect, 16, pp.798~808 (2010)
16. Amábile-Cuevas CF, "Antibiotics and antibiotic resistance in the environment", pp.2016, CRC Press
17. D’Costa VM, "Antibiotic resistance is ancient", Nature, 477, pp.457~461 (2011)
18. Benveniste R, "Aminoglycoside antibiotic-inactivating enzymes in actinomycetes similar to those present in clinical isolates of antibiotic-resistant bacteria", Proc Natl Acad Sci U S A, 70, pp.2276~2280 (1973)
19. Fraimow HS, "Multiple drug resistant bacteria", pp.109~160 (2003), Horizon Scientific Press
20. Tsubakishita S, "Origin and molecular evolution of the determinant of methicillin resistance in staphylococci", Antimicrob Agents Chemother, 54, pp.4352~4359 (2010)
21. Bush K, "Past and present perspectives on β-Lactamases", Antimicrob Agents Chemother, 62, pp.e01076~18 (2018)
22. Sohn M, "Assessment of antibiotic use and concordance with practice guidelines within 3 diverse ambulatory clinic systems", J Am Pharm Assoc(2003), 60, pp.930~936 (2020)
23. Van Boeckel TP, "Global trends in antimicrobial use in food animals", Proc Natl Acad Sci U S A, 112, pp.5649~5654 (2015)
24. Goneau LW, "Issues beyond resistance : inadequate antibiotic therapy and bacterial hypervirulence", FEMS Microbes, 1, pp.xtaa004~ (2020)
25. Suda KJ, "A national evaluation of antibiotic expenditures by healthcare setting in the United States, 2009", J Antimicrob Chemother, 68, pp.715~718 (2013)
26. Angus I, "Superbugs in the anthropocene : A profit-driven plage", Mon Rev, 71, pp.1~28 (2019)
27. Albrich WC, "Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes", Emerg Infect Dis, 10, pp.514~517 (2004)
28. van de Sande-Bruinsma N, "Antimicrobial drug use and resistance in Europe", Emerg Infect Dis, 14, pp.1722~1730 (2008)
29. Díaz-Mejía JJ, "Antibiotic resistance in oral commensal streptococci from healthy Mexicans and Cubans : resistance prevalence does not mirror antibiotic usage", FEMS Microbiol Lett, 217, pp.173~176 (2002)
30. Booth A, "A multivariable analysis of the contribution of socioeconomic and environmental factors to blood culture Escherichia Coli resistant to fluoroquinolones in high-and middle-income countries", BMC Public Health, 22, pp.354~ (2022)
31. Savoldi A, "Gross national income and antibiotic resistance in invasive isolates : analysis of the top-ranked antibiotic-resistant bacteria on the 2017 WHO priority list", J Antimicrob Chemother, 74, pp.3619~3625 (2019)
32. Collignon P, "Antimicrobial resistance : the major contribution of poor governance and corruption to this growing problem", PLoS One, 10, pp.e0116746~ (2015)
33. Newton PN, "Antimicrobial resistance in developing countries", pp.413~443 (2010), Springer
34. Klein EY, "Global increase and geographic convergence in antibiotic consumption between 2000 and 2015", Proc Natl Acad Sci U S A, 115, pp.E3463~E3470 (2018)
35. Amabile-Cuevas CF, "Antibiotic usage and resistance in Mexico : an update after a decade of change", J Infect Dev Ctries, 15, pp.442~449 (2021)
36. Berndtson AE, "Cross-border antibiotic resistance patterns in trauma patients", Surgery, 166, pp.109~115 (2019)
37. Hammond A, "Antimicrobial resistance associations with national primary care antibiotic stewardship policy : Primary care-based, multilevel analytic study", PLoS One, 15, pp.e0232903~ (2020)
38. Carroll AC, "Plasmid persistence : costs, benefits, and the plasmid paradox", Can J Microbiol, 64, pp.293~304 (2018)
39. Bouma JE, "Evolution of a bacteria", plasmid association, 1988, pp.335, 351~352
40. Lopatkin AJ, "Persistence and reversal of plasmidmediated antibiotic resistance", Nat Commun, 8, pp.1689~ (2017)
41. Sandegren L, "Nitrofurantoin resistance mechanism and fitness cost in Escherichia coli", J Antimicrob Chemother, 62, pp.495~503 (2008)
42. Melnyk AH, "The fitness costs of antibiotic resistance mutations", Evol Appl, 8, pp.273~283 (2015)
43. Foucault ML, "Fitness cost of VanA-type vancomycin resistance in methicillin-resistant Staphylococcus aureus", Antimicrob Agents Chemother, 53, pp.2354~2359 (2009)
44. Salyers AA, "Why are antibiotic resistance genes so resistant to elimination?", Antimicrob Agents Chemother, 41, pp.2321~2325 (1997)
45. Sundqvist M, "Little evidence for reversibility of trimethoprim resistance after a drastic reduction in trimethoprim use", J Antimicrob Chemother, 65, pp.350~360 (2010)
46. Shu CC, "Exposure to one antibiotic leads to acquisition of resistance to another antibiotic via quorum sensing mechanisms", Front Microbiol, 11, pp.580466~ (2021)
47. Heinemann JA, "Do antibiotics maintain antibiotic resistance?", Drug Discov Today, 5, pp.195~204 (2000)
48. Wilkinson JL, "Pharmaceutical pollution of the world’s rivers", Proc Natl Acad Sci U S A, 119, pp.e2113947119~ (2022)
49. Brown EM, "Antibiotic cycling or rotation : a systematic review of the evidence of efficacy", J Antimicrob Chemother, 55, pp.6~9 (2005)
50. Chatzopoulou M, "Systematic review of the effects of antimicrobial cycling on bacterial resistance rates within hospital settings", Br J Clin Pharmacol, 88, pp.897~910 (2022)
51. John JF Jr, "The microbial genetics of antibiotic cycling", Infect Control Hosp Epidemiol, 21(1Suppl), pp.S22~S31 (2000)
52. Levin BR, "Cycling antibiotics may not be good for your health", Proc Natl Acad Sci U S A, 101, pp.13101~13102 (2004)
53. Ledley FD, "Profitability of large pharmaceutical companies compared with other large public companies", JAMA, 323, pp.834~843 (2020)
54. Doshi P, "Speeding new antibiotics to market: a fake fix?", BMJ, 350, pp.h1453~ (2015)
55. Amábile-Cuevas C, "Society must seize control of the antibiotics crisis", Nature, 533, pp.439~ (2016)
56. Becker D, "Robust Salmonella metabolism limits possibilities for new antimicrobials", Nature, 440, pp.303~307 (2006)
57. Johnson EO, "Large-scale chemical-genetics yields new M. tuberculosis inhibitor classes", Nature, 571, pp.72~78 (2019)
58. Agudelo M, "Even apparently insignificant chemical deviations among bioequivalent generic antibiotics can lead to therapeutic nonequivalence : the case of meropenem", Antimicrob Agents Chemother, 58, pp.1005~1018 (2014)
59. Rodriguez CA, "In vitro and in vivo comparison of the antistaphylococcal efficacy of generic products and the innovator of oxacillin", BMC Infect Dis, 10, pp.153~ (2010)
60. Vesga O, "Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator", Antimicrob Agents Chemother, 54, pp.3271~3279 (2010)
61. Johnston A, "Substandard drugs : a potential crisis for public health", Br J Clin Pharmacol, 78, pp.218~243 (2014)
62. Jones RN, "More potency assay results for generic non-USA lots of piperacillin", tazobactam and initial reports for generic meropenem compounds marketed in the USA, 2013, pp.76, 110~112
63. Lambert PA, "Pharmaceutical quality of ceftriaxone generic drug products compared with Rocephin", J Chemother, 15, pp.357~368 (2003)
64. Rodriguez CA, "Impact on bacterial resistance of therapeutically nonequivalent generics : The case of piperacillin-tazobactam", PLoS One, 11, pp.e0155806~ (2016)
65. Jensen US, "Effect of generics on price and consumption of ciprofloxacin in primary healthcare : the relationship to increasing resistance", J Antimicrob Chemother, 65, pp.1286~1291 (2010)
66. ChangingMarkets, "Ecostorm. Superbugs in the supply chain: How pollution from antibiotics factories in India and China is fueling the global rise of drug-resistant infections", Changing Markets Foundation, ~ (2016)
67. Finch R, "Generic antibiotics, antibiotic resistance, and drug licensing", Lancet Infect Dis, 10, pp.754~ (2010)
68. Amábile-Cuevas CF, "Shooting the messenger of antibiotic resistance : plasmid elimination as a potential counter-evolutionary tactic", Drug Discov Today, 9, pp.465~467 (2004)
69. Alksne LE, "Bacterial virulence as a target for antimicrobial chemotherapy", Curr Opin Biotechnol, 11, pp.625~636 (2000)
70. Amábile-Cuevas CF, "Phage therapies : Lessons(not)learned from the"antibiotic era"", PHAGE, 3, pp.12~14 (2022)
71. Duan Y, "Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease", Nature, 575, pp.505~511 (2019)
72. Kalia VC, "Evolution of resistance to quorum-sensing inhibitors", Microb Ecol, 68, pp.13~23 (2014)
73. LaSarre B, "Exploiting quorum sensing to confuse bacterial pathogens", Microbiol Mol Biol Rev, 77, pp.73~111 (2013)
74. Czaplewski L, "Alternatives to antibiotics-a pipeline portfolio review", Lancet Infect Dis, 16, pp.239~251 (2016)
75. Tackling drug-resistant infections globally: Final report and recommendations, "O’Neil J", Wellcome Trust, 2016
76. Antimicrobial Resistance Collaborators, "Global burden of bacterial antimicrobial resistance in 2019 : a systematic analysis", Lancet, 399, pp.629~655 (2022)
77. Abat C, "Extremely and pandrug-resistant bacteria extradeaths : myth or reality?", Eur J Clin Microbiol Infect Dis, 37, pp.1687~1697 (2018)

관련 논문AI추천